Literature DB >> 9629649

A comparison of two methods for adaptive interim analyses in clinical trials.

G Wassmer1.   

Abstract

Recently, two methods for planning and conducting two-stage procedures were proposed (Bauer and Köhne, 1994, Biometrics 50, 1029-1041; Proschan and Hunsberger, 1995, Biometrics 51, 1315-1324). Both procedures allow the termination of the trial with the early acceptance of H0 in the absence of a treatment effect after performing the first stage of the study. Furthermore, the observed treatment effect at stage I can be used for planning and redesigning the second stage of the study in a way that protects the Type I error rate. The exact Type I error rate of the Proschan and Hunsberger approach is derived. It is shown that the two methods lead to similar decision rules with negligibly small differences in power and expected sample size. In terms of providing design tools and practical applicability, however, they differ. The practical performance of the procedures is discussed and recommendations for their use are given.

Mesh:

Year:  1998        PMID: 9629649

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  5 in total

1.  Sample size re-estimation in a breast cancer trial.

Authors:  Erinn M Hade; David Jarjoura
Journal:  Clin Trials       Date:  2010-04-14       Impact factor: 2.486

2.  Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.

Authors:  Peter Bauer; Frank Bretz; Vladimir Dragalin; Franz König; Gernot Wassmer
Journal:  Stat Med       Date:  2015-03-16       Impact factor: 2.373

3.  Options and Considerations for Adaptive Laboratory Experiments.

Authors:  Lai Wei; David Jarjoura
Journal:  Stat Biosci       Date:  2014-11-25

4.  Adaptive designs based on the truncated product method.

Authors:  Markus Neuhäuser; Frank Bretz
Journal:  BMC Med Res Methodol       Date:  2005-09-19       Impact factor: 4.615

5.  Follow up after sample size re-estimation in a breast cancer randomized trial for disease-free survival.

Authors:  Erinn M Hade; Gregory S Young; Richard R Love
Journal:  Trials       Date:  2019-08-23       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.